ArticleBioinformation2012
Therapeutic application of natural inhibitors against snake venom phospholipase A(2).
Article in Bioinformation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- A review and in silico screening of plant-derived snake venom/toxin inhibitors: ADMET, drug-likeness, and medicinal chemistry profiling.PLoS neglected tropical diseases · 2025Pooled it
- Eburicoic Acid fromJournal of inflammation research · 2026Article
- Ethnomedicinal breakthroughs in snake bite therapy: From folklore to forefront.Toxicology reports · 2024Review
- Doxycycline-Mediated Inhibition of Snake Venom Phospholipase and Metalloproteinase.Military medicine · 2024Article
- Treatment with Vitis vinifera extract for controlling ascites and local swelling in snakebites.Clinical and experimental emergency medicine · 2023Article
- A First Look at the Inhibitory Potential ofToxins · 2022Article
- Molecular dynamics simulation analysis of alpha-cobra toxin docked with phytochemical compounds.Bioinformation · 2022Article
- Local inflammatory mediators alterations induced byToxicon: X · 2021Article
- BoaγPLI from Boa constrictor Blood is a Broad-Spectrum Inhibitor of Venom PLAJournal of chemical ecology · 2021Article
- Article
- Green synthesis of silver nanoparticles using Indian male fern (Toxicology research · 2020Article
- Article
- Ethnopharmacological Use and Biological Activities ofEvidence-based complementary and alternative medicine : eCAM · 2020Review
- Perspective on the Therapeutics of Anti-Snake Venom.Molecules (Basel, Switzerland) · 2019Review
- Pharmacological characterization of cnidarian extracts from the Caribbean Sea: evaluation of anti-snake venom and antitumor properties.The journal of venomous animals and toxins including tropical diseases · 2018Article
- Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite.Journal of tropical medicine · 2018Review
- Non-Clinical Studies for Evaluation of 8-C-Rhamnosyl Apigenin Purified from Peperomia obtusifolia against Acute Edema.International journal of molecular sciences · 2017Article
- A Review on Venom Enzymes Neutralizing Ability of Secondary Metabolites from Medicinal Plants.Journal of pharmacopuncture · 2017Review
- Snake Venom PLABioMed research international · 2017Review
- Protective Effect of the Plant Extracts of Erythroxylum sp. against Toxic Effects Induced by the Venom of Lachesis muta Snake.Molecules (Basel, Switzerland) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural inhibitors occupy an important place in the potential to neutralize the toxic effects caused by snake venom proteins and enzymes. It has been well recognized for several years that animal sera, some of the plant and marine extracts are the most potent in neutralizing snake venom phospholipase A(2) (svPLA(2)). The implication of this review to update the latest research work which has been accomplished with svPLA(2) inhibitors from various natural sources like animal, marine organisms presents a compilation of research in this field over the past decade and revisiting the previous research report including those found in plants. In addition to that the bioactive compounds/inhibitor molecules from diverse sources like aristolochic alkaloid, flavonoids and neoflavonoids from plants, hydrocarbones -2, 4 dimethyl hexane, 2 methylnonane, and 2, 6 dimethyl heptane obtained from traditional medicinal plants Tragia involucrata (Euphorbiaceae) member of natural products involved for the inhibitory potential of phospholipase A(2) (PLA(2)) enzymes in vitro and also decrease both oedema induced by snake venom as well as human synovial fluid PLA(2). Besides marine natural products that inhibit PLA(2) are manoalide and its derivatives such as scalaradial and related compounds, pseudopterosins and vidalols, tetracylne from synthetic chemicals etc. There is an overview of the role of PLA(2) in inflammation that provides a rationale for seeking inhibitors of PLA(2) as anti-inflammatory agents. However, more studies should be considered to evaluate antivenom efficiency of sera and other agents against a variety of snake venoms found in various parts of the world. The implications of these new groups of svPLA(2) toxin inhibitors in the context of our current understanding of snake biology as well as in the development of new novel antivenoms therapeutics agents in the efficient treatment of snake envenomations are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.